Salvage surgery is safe and effective for clinical stage III non-small-cell lung cancer
Interdisciplinary CardioVascular and Thoracic Surgery · 2025
DOI: 10.1093/icvts/ivaf084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Interdisciplinary CardioVascular and Thoracic Surgery, 2025. Verfasst von Xun Luo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular and Thoracic Surgery, Heart and Vascular Institute, West Virginia University, Morgantown, WV, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Salvage Therapy, Lung Neoplasms, Pneumonectomy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
OBJECTIVES The utility of surgery for stage III non-small-cell lung cancer (NSCLC) has yet no consensus. Surgery is mainly deployed in a planned multimodality regimen or as a salvage option after definite chemoradiation. We sought to explore outcomes after salvage surgery, planned surgery or oncological treatment alone for clinical stage III NSCLC. METHODS We identified clinical stage III NSCLC from the National Cancer Database between 2010 and 2020. We used timing between radiation and surgical resection to define salvage surgery vs planned surgery. Surgery performed after 3 months following radiation was considered salvage surgery. We performed propensity score matching to match planned surgery and oncologic treatment alone group to salvage surgery to account for patient and clinical characteristics. After matching, we compared their overall survival. Between salvage surgery and planned surgery, we further compared perioperative outcomes (short-term mortality, 30-day readmission and length of stay). RESULTS Among 143 299 patients, 692 (0.5%) underwent salvage surgery and 25 598 (17.9%) underwent planned surgery. Median time from radiation to salvage surgery was 118 days. After the propensity score matching, 10-year survival of salvage surgery (34.6%) or planned surgery (34.5%) was higher than oncological treatment alone (16.8%). Thirty-day mortality (2.3% vs 3.1%), 90-day mortality (5.1% vs 6.0%), 30-day readmission (3.3% vs 4.2%) and length of stay (5 vs 5) were similar between salvage and planned surgery. CONCLUSIONS Salvage surgery conferred better survival than oncologic treatment alone and similar long-term survival and perioperative outcomes with planned surgery. Salvage surgery is a safe and effective option for stage III NSCLC as planned surgery in selected patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular and Thoracic Surgery, Heart and Vascular Institute, West Virginia University, Morgantown, WV, USA.
- Department of Statistics, West Virginia University, Morgantown, WV, USA.
ORCID-Profile: Xun Luo, Vinay Badhwar
Zitieren
APA
Luo, X., Hayanga, J. W. A., Tham, E., Ryan, K. J., Rothenberg, P., Mehaffey, J. H., Lamb, J., Reddy, S., Badhwar, V., & Toker, A. (2025). Salvage surgery is safe and effective for clinical stage III non-small-cell lung cancer. Interdisciplinary CardioVascular and Thoracic Surgery. https://doi.org/10.1093/icvts/ivaf084
Vancouver
Luo X, Hayanga JWA, Tham E, Ryan KJ, Rothenberg P, Mehaffey JH, et al. Salvage surgery is safe and effective for clinical stage III non-small-cell lung cancer. Interdisciplinary CardioVascular and Thoracic Surgery. 2025. doi:10.1093/icvts/ivaf084
BibTeX
@article{Luo2025,
author = {Luo, Xun and Hayanga, J W Awori and Tham, Elwin and Ryan, Kenneth J and Rothenberg, Paul and Mehaffey, James Hunter and Lamb, Jason and Reddy, Shalini and Badhwar, Vinay and Toker, Alper},
title = {Salvage surgery is safe and effective for clinical stage III non-small-cell lung cancer},
journal = {Interdisciplinary CardioVascular and Thoracic Surgery},
year = {2025},
doi = {10.1093/icvts/ivaf084}
}
EUVIMED